Initiate a Phase 3 study of SOLIRIS in GBS in Japan
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 30 Jul 2020
- Due
- 31 Dec 2021
- Delivered
- Q1 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Alexion plans to initiate a Phase 3 study of SOLIRIS in GBS in Japan in 2021, pending regulatory feedback.”
What we found
Evidence strength A What the grades mean
A 10-Q filed 2021-04-30 reports that the Phase III SOLIRIS GBS study in Japan was initiated in Q1 2021, within the 2021 deadline.
-
A Alexion Pharmaceuticals 10-Q filed 2021-04-30
“Alexion initiated a Phase III study of SOLIRIS in GBS in Japan in the first quarter of 2021.” ✓ confirmed on the page
Checked 21 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift -184 days
- 2 versions
-
Version 1 · original · stated 30 Jul 2020
Deadline 31 Dec 2021 (“in 2021”) · wording expected
-
Version 2 · stated 4 Feb 2021
Deadline 30 Jun 2021 (“in the first half of 2021”) · wording expected
“Alexion plans to initiate a Phase 3 study of SOLIRIS in GBS in Japan in the first half of 2021.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 3 study of SOLIRIS in GBS in Japan
- Where
- Japan
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: pending regulatory feedback
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Alexion Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2020-C899866-019389 · Corrections policy